Zobrazeno 1 - 10
of 319
pro vyhledávání: '"Udo Mueller"'
Autor:
Grochowski, Mateusz
Publikováno v:
Rabels Zeitschrift für ausländisches und internationales Privatrecht / The Rabel Journal of Comparative and International Private Law, 2023 Jan 01. 87(1), 213-217.
Externí odkaz:
https://www.jstor.org/stable/48762124
Publikováno v:
Personal, 2003 Apr 01. 55(4), 63-63.
Externí odkaz:
https://www.jstor.org/stable/24386806
Autor:
Bolsenkötter, Heinz
Publikováno v:
Zeitschrift für öffentliche und gemeinwirtschaftliche Unternehmen: ZögU / Journal for Public and Nonprofit Services, 2003 Jan 01. 26(3), 325-326.
Externí odkaz:
https://www.jstor.org/stable/20765190
Autor:
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Tim Larson, Allen L. Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, Rachel Tam, David D'Adamo, Neelesh Sharma, Barbara J. Brennan, Ying A. Wang, Sabine Coppieters, Hong Zebger-Gong, Anke Weispfenning, Henrik Seidel, Bart A. Ploeger, Udo Mueller, Carolina Soares Viana de Oliveira, Andrew Scott Paulson
Publikováno v:
EClinicalMedicine, Vol 58, Iss , Pp 101917- (2023)
Summary: Background: Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal cancer. This study assessed regorafenib plus nivolumab in patients with mic
Externí odkaz:
https://doaj.org/article/607bb200b67a4b90be60f4ef3e49d300
Autor:
Hartmut M. Volz
Udo Müller leitet ein Imperium von mehr als 150 Firmen mit über 10.000 Mitarbeitern. Alles unter dem Dach der börsennotierten Ströer SE & Co. KGaA. Dieses Buch berichtet von seinem Start mit einer Werbeagentur in einer kleinen Ost-Berliner Garage
Autor:
Lynley V. Marshall, Irene Jiménez, Andrew D.J. Pearson, Udo Mueller, Adriaan Cleton, Bart Ploeger, Michael Teufel, Patricia Maeda, Sarah Schlief, Bruce Morland, Andrea C. Agostinho, Gilles Vassal, Jasmine Kincaide, Birgit Geoerger, Didier Frappaz
Publikováno v:
European Journal of Cancer. 153:142-152
Background This phase 1 study evaluated safety, pharmacokinetics (PK), maximum tolerated dose (MTD), and antitumour activity of regorafenib in paediatric patients with solid tumours. Patients and methods Patients (aged 6 months to Results Forty-one p
Autor:
Morgan Kruse, Rebecca Wildner, Gisoo Barnes, Monique Martin, Udo Mueller, Francesco Lo-Coco, Ashutosh Pathak
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134587 (2015)
The objective of this study was to estimate the net cost of arsenic trioxide (ATO) added to all-trans retinoic acid (ATRA) compared to ATRA plus chemotherapy when used in first-line acute promyelocytic leukemia (APL) treatment for low to intermediate
Externí odkaz:
https://doaj.org/article/92f15341f1bd41c6b64db8552990d58c
Autor:
Patrick Liu, Nicole Lang, Ashutosh Pathak, Ruth Pettengell, Udo Mueller, Henry C. Fung, Andreas Lammerich, Ingo Diel, Anton Buchner, Camille N. Abboud, Hartmut Link
Publikováno v:
Supportive Care in Cancer. 27:2569-2577
Recombinant granulocyte colony-stimulating factors (rG-CSFs), such as filgrastim, are administered to prevent complications in patients receiving chemotherapy. In Europe, a biosimilar to filgrastim, tevagrastim/ratiograstim/biograstim, was approved i
Autor:
Agota Szende, Jean Klastersky, Covance, Leeds, United Kingdom, Udo Mueller, Boxiong Tang, Stephen D. Stefani, Jennifer Urwongse, Erika Szabo
Publikováno v:
Jornal Brasileiro de Economia da Saúde. 10:107-117
Autor:
William P. Harris, Max W. Sung, Dirk Waldschmidt, Ying A. Wang, Tatiane Cristine Ishida, Richard D. Kim, Udo Mueller, Barbara J. Brennan, Vittorio Luigi Garosi, Hong Zebger-Gong, Peter R. Galle, Anthony B. El-Khoueiry, Roniel Cabrera
Publikováno v:
Journal of Clinical Oncology. 39:4078-4078
4078 Background: REG, a multikinase inhibitor, and PEMBRO, an anti-PD-1 mAb, are approved as monotherapies in advanced HCC after progression on sorafenib. This phase 1b dose-finding study investigated first-line REG plus PEMBRO in advanced HCC. Metho